Quantification of AAV Particle Titers by Infrared Fluorescence Scanning of Coomassie-Stained Sodium Dodecyl Sulfate–Polyacrylamide Gels
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV)-based vectors have gained increasing attention as gene delivery vehicles in basic and preclinical studies as well as in human gene therapy trials. Especially for the latter two—for both safety and therapeutic efficacy reasons—a detailed characterization of all relevant parameters of the vector preparation is essential. Two important parameters that are routinely used to analyze recombinant AAV vectors are (1) the titer of viral particles containing a (recombinant) viral genome and (2) the purity of the vector preparation, most commonly assessed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) followed by silver staining. An important, third parameter, the titer of total viral particles, that is, the combined titer of both genome-containing and empty viral capsids, is rarely determined. Here, we describe a simple and inexpensive method that allows the simultaneous assessment of both vector purity and the determination of the total viral particle titer. This method, which was validated by comparison with established methods to determine viral particle titers, is based on the fact that Coomassie Brilliant Blue, when bound to proteins, fluoresces in the infrared spectrum. Viral samples are separated by SDS–PAGE followed by Coomassie Brilliant Blue staining and gel analysis with an infrared laser-scanning device. In combination with a protein standard, our method allows the rapid and accurate determination of viral particle titers simultaneously with the assessment of vector purity. Kohlbrenner and colleagues report on a simple and inexpensive method, based on SDS-PAGE and Coomassie Brilliant Blue staining, that allows the simultaneous assessment of AAV vector purity and viral particle titer. According to the authors, this method can be used regardless of the method of vector production, the vector genome or the AAV serotype used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“…use adeno-associated virus(AAV) as a gene therapy vector accumulate (e.g., for Leber’s congenital amaurosis [Maguire et al., 2009], hemophilia B [Nathwani et al., 2011], and heart failure [Jessup et al., 2011]), researchers have become interested in using recombinant AAV vectors as a gene…”
BackgroundMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 1×
“As encouraging studies that use adeno-associated virus(AAV) as a gene therapy vector accumulate (e.g., for Leber’s congenital amaurosis [Maguire et al., 2009], hemophilia B [Nathwani et al., 2011], and heart failure [Jessup et al., 2011]), researchers have become interested in using recombinant AAV…”
BackgroundJessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D. F., Jaski, B., Yaroshinsky, A., Zsebo, K. M., Dittrich, H., & Hajjar, R. J. (2011) · Circulation · doi:10.1161/circulationaha.111.022889 · Cited by 760
Self-citationDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 2×
“…will eventually become commercially available, much work is currently being done in engineering the viral capsid to create novel mutant and chimeric AAVs that, for instance, target specific tissues (Asokan et al., 2012) or show improved resistance to neutralizing antibodies (Maheshri et al., 2006).”
BackgroundManufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205 · cited 1×
“198 transduction (Ayuso et al., 2010) and safety purposes (Wright, 2008).”
Grimm, D., Kern, A., Pawlita, M., Ferrari, F. K., Samulski, R. J., & Kleinschmidt, J. A. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300946 · Cited by 195 · cited 1×
“ELISAs have been described previously for AAV2 and AAV3 (Grimm et al., 1999) and for AAV1, AAV4, AAV5, and AAV6 (Kuck et al., 2007) but not for other serotypes, and only ELISA kits for AAV1, AAV2, AAV3, and AAV5 are commercially available.”
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models
Rapti, K., Louis-Jeune, V., Kohlbrenner, E., Ishikawa, K., Ladage, D., Zolotukhin, S., Hajjar, R. J., & Weber, T. (2012) · Molecular Therapy · doi:10.1038/mt.2011.177 · Cited by 170 · cited 1×
“In the past we have required defined quantities of empty AAV particles for some of our studies (Rapti et al., 2012), and the inability to employ qPCR necessitated alternative quantification methods.”
MethodSelf-citationCharacterization of a recombinant adeno-associated virus type 2 Reference Standard Material
Lock, M., McGorray, S., Auricchio, A., Ayuso, E., Beecham, E. J., Blouin-Tavel, V., Bosch, F., Bose, M., Byrne, B. J., Caton, T., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.223 · Cited by 131
Development of AAV serotype-specific ELISAs using novel monoclonal antibodies
Kuck, D., Kern, A., & Kleinschmidt, J. A. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.10.005 · Cited by 74
Cited by
Gimpel, A. L., Katsikis, G., Sha, S., Maloney, A. J., Hong, M. S., Nguyen, T. N. T., Wolfrum, J., Springs, S. L., Sinskey, A. J., Manalis, S. R., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.010 · Cited by 185
Production of adeno-associated virus vectors for in vitro and in vivo applications
Kimura, T., Ferran, B., Tsukahara, Y., Shang, Q., Desai, S., Fedoce, A., Pimentel, D. R., Luptak, I., Adachi, T., Ido, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49624-w · Cited by 155
Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms
Robert, M., Chahal, P. S., Audy, A., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Biotechnology Journal · doi:10.1002/biot.201600193 · Cited by 89
Werling, N. J., Satkunanathan, S., Thorpe, R., & Zhao, Y. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.013 · Cited by 53
“These include the development of a universal qPCR method based on amplifying an AAV2 ITR-specific sequence,(17) particle titration by optical density,(21) ion-exchange chromatography,(20) or infrared fluorescence scanning.(22) With the aim of standardizing future AAV dose determination assays, we systematically analyz…”
MethodFilling Adeno-Associated Virus Capsids: Estimating Success by Cryo-Electron Microscopy
Subramanian, S., Maurer, A. C., Bator, C. M., Makhov, A. M., Conway, J. F., Turner, K. B., Marden, J. H., Vandenberghe, L. H., & Hafenstein, S. L. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.041 · Cited by 40
Metadata
- Authors
- Kohlbrenner, E., Henckaerts, E., Rapti, K., Gordon, R. E., Linden, R. M., Hajjar, R. J., & Weber, T.
- Venue
- Human Gene Therapy Methods
- Publisher
- SAGE Publications
- Published
- 2012-06
- Volume
- 23
- Issue
- 3
- Pages
- 198-203
- ISSN
- 1946-6536 (ISSN-L)
- 1946-6544
- OpenAlex
- W2069895701
- Cited by
- 36
- References
- 9
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.